Deleterious alterations of DNA damage response and repair (DDR) genes in association with clinical benefit to programmed cell death protein-1 (PD-1)/PD ligand 1 (PD-L1)-based therapy in esophageal squamous cell carcinoma (ESCC)

被引：0
|
作者：
Guo, Jhe-Cyuan
Lin, Chia-Chi
Huang, Ta-Chen
Chang, Chun-Jung
Kuo, Hung-Yang
Hsu, Chih-Hung
机构：
[1] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[3] Natl Taiwan Univ Hosp, Taipei, Taiwan
[4] Natl Taiwan Univ, Coll Med, Grad Inst Oncol, Taipei, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
28
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1)
    Wen, Biyan
    Zhao, Lin
    Wang, Yuchu
    Qiu, Chuangnan
    Xu, Zhimin
    Huang, Kunling
    Zhu, He
    Li, Zemin
    Li, Huangjin
    PREPARATIVE BIOCHEMISTRY & BIOTECHNOLOGY, 2020, 50 (03): : 252 - 259
  • [22] Roles of PTEN inactivation and PD-1/PD-L1 activation in esophageal squamous cell carcinoma
    Rong Qiu
    Wenxi Wang
    Juan Li
    Yuxiang Wang
    Molecular Biology Reports, 2022, 49 : 6633 - 6645
  • [23] Roles of PTEN inactivation and PD-1/PD-L1 activation in esophageal squamous cell carcinoma
    Qiu, Rong
    Wang, Wenxi
    Li, Juan
    Wang, Yuxiang
    MOLECULAR BIOLOGY REPORTS, 2022, 49 (07) : 6633 - 6645
  • [24] Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
    Teo, Min Yuen
    Seier, Kenneth
    Ostrovnaya, Irina
    Regazzi, Ashley M.
    Kania, Brooke E.
    Moran, Meredith M.
    Cipolla, Catharine K.
    Bluth, Mark J.
    Chaim, Joshua
    Al-Ahmadie, Hikmat
    Snyder, Alexandra
    Carlo, Maria I.
    Solit, David B.
    Berger, Michael F.
    Funt, Samuel
    Wolchok, Jedd D.
    Iyer, Gopa
    Bajorin, Dean F.
    Callahan, Margaret K.
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1685 - +
  • [25] Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma
    Hanna, Glenn J.
    Kacew, Alec J.
    Tanguturi, Anusha R.
    Grote, Hans J.
    Vergara, Victoria
    Brunkhorst, Beatrice
    Rabinowits, Guilherme
    Thakuria, Manisha
    LeBoeuf, Nicole R.
    Ihling, Christian
    DeCaprio, James A.
    Lorch, Jochen H.
    FRONTIERS IN MEDICINE, 2020, 7
  • [26] Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) inhibitors and adverse cardiovascular events: a population-based study
    Lee, S.
    Zhou, J.
    Lakhani, I
    Yang, L.
    Liu, T.
    Zhang, Y.
    Xia, Y.
    Wong, W. T.
    Chan, E. W. Y.
    Wong, I. C. K.
    Tse, G.
    Zhang, Q.
    EUROPEAN HEART JOURNAL, 2022, 43
  • [27] Programmed Cell Death Receptor (PD-1), PD-1 Ligand (PD-L1) Expression in Philadelphia Chromosome Negative Myeloid Neoplasms
    Chen, Chi
    Pandey, Anita
    Kundra, Ajay
    Kodali, Sreenath
    Wong, Ching
    Cheung, Tony W.
    Gotlieb, Vladimir K.
    Joseph, Gardith
    Tribie, Sophia
    Wang, Jen-Chin
    BLOOD, 2018, 132
  • [28] Programmed death ligand-1 (PD-L1) expression in penile squamous cell carcinoma
    Wang, Jennifer
    Rodriguez, Jaime
    Rao, Priya
    Pettaway, Curtis Alvin
    Pagliaro, Lance C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [29] Association of polymorphisms in the programmed cell death 1 (PD-1) and PD-1 ligand genes with ankylosing spondylitis in a Chinese population
    Yang, Q.
    Liu, Y.
    Liu, D.
    Zhang, Y.
    Mu, K.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (01) : 13 - 18
  • [30] Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer
    Neelima Vidula
    Christina Yau
    Hope S. Rugo
    Breast Cancer Research and Treatment, 2021, 187 : 387 - 395
12345